How do published stem cell studies select patients?
Who is enrolled shapes what a stem cell study can show. This guide covers how published MSC research frames disease stage, phenotype and tissue type.

Key takeaways.
- Study participant selection is framed around four domains, starting with disease characteristics.
- In published osteoarthritis studies, the most favourable outcomes were reported at Kellgren-Lawrence grade 2 to 3.
- The inflammatory osteoarthritis phenotype is hypothesised to be more responsive to MSC immunomodulation.
- Chronic tendinopathy is a failed healing response, not an inflammatory condition.
- The ACL heals poorly because it sits inside the synovial environment with poor blood supply.
- These are research findings. MSC therapy for osteoarthritis is not FDA-approved.
Four assessment domains
The course frames participant selection around four domains: disease characteristics, patient factors, treatment history, and expectations and goals.
Disease characteristics covers the biological nature of the condition. That includes disease stage, tissue quality and regenerative potential. It is the domain the published literature says most about.
Osteoarthritis: stage and phenotype
Osteoarthritis is the most commonly studied application of mesenchymal stem/stromal cell (MSC) research. In published studies, researchers have reported the most favourable outcomes at Kellgren-Lawrence grade 2 to 3, which is moderate disease. The stated rationale is that very early disease shows little measurable change, while advanced disease leaves insufficient tissue.
Phenotype is also studied. The inflammatory phenotype shows synovial inflammation and elevated inflammatory markers. Researchers hypothesise that it may be more responsive to MSC immunomodulation than the mechanical, metabolic or post-traumatic phenotypes.
Soft tissue: know the pathology
Chronic tendinopathy is different from acute tendinitis. It is a failed healing response with disorganized collagen and neovascularization, not inflammation. The suffix "-opathy" signals a degenerative process.
Ligaments differ too. The ACL has limited natural healing capacity compared with the MCL. It sits within the synovial environment with poor blood supply, and its location inside the joint restricts access to healing factors.
Read these as research findings
These points describe how studies were designed and what they reported. They are not treatment criteria. MSC therapy for osteoarthritis is not FDA-approved, and stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses that clinics market.
Educational content for healthcare professionals. Not a treatment recommendation. Stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses most clinics offer.
This guide covers the what and the why.
The how is taught live. The webinar and live training go deeper on:
- The full four-domain assessment framework
- Outcome measures and how to judge study quality
- Evidence by condition, including neurological and aesthetic research
- Administration routes used in published research
- Setting expectations with patients
Common questions.
Which osteoarthritis grade has been reported to do best in MSC studies?
Why does osteoarthritis phenotype matter in MSC research?
How is tendinopathy different from tendinitis?
Sources
- Matas J, Orrego M, Amenabar D, Infante C, Tapia-Limonchi R, Cadiz MI, et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: A randomized double-blind placebo-controlled clinical trial. Stem Cells Transl Med. 2019;8(6):504-13.
- Pers YM, Rackwitz L, Ferreira R, Pullig O, Delfour C, Barry F, et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: A phase I dose-escalation trial. Stem Cells Transl Med. 2016;5(7):847-56.
- Freitag J, Bates D, Boyd R, Shah K, Barnard A, Huguenin L, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: Reparative pathways, safety and efficacy - a review. BMC Musculoskelet Disord. 2016;17:230.
Keep reading.
Stem cell · 3 min read
What is a stem cell?
Stem cells are defined by two properties: self-renewal and the capacity to differentiate. Here is what that means and where clinical use stands.
Start the lessonStem cell · 3 min read
Stem cell potency explained: totipotent, pluripotent, multipotent and unipotent
Potency describes how many cell types a stem cell can become. This guide covers the four levels and where MSCs sit among them.
Start the lessonStem cell · 3 min read
What is a mesenchymal stromal cell (MSC)? The ISCT minimal criteria
The 2006 ISCT minimal criteria set the identity standard for mesenchymal stromal cells: three positive markers, five negative markers and trilineage differentiation.
Start the lessonReady for the hands-on detail?
Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.